DOCSLIB.ORG

1,1,1-Trichloroethane Interim AEGL Document

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1,1,1-Trichloroethane Interim AEGL Document INTERIM 1: 6\2000 1,1,1-TRICHLOROETHANE CAS REG. NO. 71-55-06 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) For NAS/COT Subcommittee for AEGLs June 2000 INTERIM 1: 6/2000 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) 1,1,1-TRICHLOROETHANE CAS REG. NO. 71-55-06 Oak Ridge National Laboratory, Managed and Operated by UT-Battelle, LLC, for the U.S. Department of Energy under contract number DE-AC05-00OR22725. 1,1,1-TRICHLOROETHANE INTERIM 1: 6\2000 1 2 PREFACE 3 4 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, 5 the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous 6 Substances (NAC/AEGL Committee) has been established to identify, review and interpret 7 relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic 8 chemicals. 9 10 AEGLs represent threshold exposure limits for the general public and are applicable to 11 emergency exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, 12 and AEGL-1 levels as appropriate, will be developed for each of five exposure periods (10 and 13 30 minutes, 1 hour, 4 hours, and 8 hours) and will be distinguished by varying degrees of 14 severity of toxic effects. It is believed that the recommended exposure levels are applicable to 15 the general population including infants and children, and other individuals who may be 16 sensitive and susceptible. The three AEGLs have been defined as follows: 17 18 AEGL-1 is the airborne concentration (expressed as ppm or mg/m3) of a substance above 19 which it is predicted that the general population, including susceptible individuals, could 20 experience notable discomfort, irritation, or certain asymptomatic, non-sensory effects. 21 However, the effects are not disabling and are transient and reversible upon cessation of 22 exposure. 23 24 AEGL-2 is the airborne concentration (expressed as ppm or mg/m3) of a substance above 25 which it is predicted that the general population, including susceptible individuals, could 26 experience irreversible or other serious, long-lasting adverse health effects, or an impaired 27 ability to escape. 28 29 AEGL-3 is the airborne concentration (expressed as ppm or mg/m3) of a substance above 30 which it is predicted that the general population, including susceptible individuals, could 31 experience life-threatening health effects or death. 32 33 Airborne concentrations below the AEGL-1 represent exposure levels that could produce 34 mild and progressively increasing odor, taste, and sensory irritation, or certain non-symptomatic, 35 non-sensory effects. With increasing airborne concentrations above each AEGL level, there is a 36 progressive increase in the likelihood of occurrence and the severity of effects described for each 37 corresponding AEGL level. Although the AEGL values represent threshold levels for the 38 general public, including sensitive subpopulations, it is recognized that certain individuals, 39 subject to unique or idiosyncratic responses, could experience the effects described at 40 concentrations below the corresponding AEGL level. 41 3 1,1,1-TRICHLOROETHANE INTERIM 1: 6\2000 1 TABLE OF CONTENTS 2 3 4 PREFACE ...................................................................3 5 6 LIST OF TABLES.............................................................4 7 8 EXECUTIVE SUMMARY......................................................7 9 10 1. INTRODUCTION .........................................................10 11 12 2. HUMAN TOXICITY DATA ................................................11 13 2.1. Acute Lethality ........................................................11 14 2.1.1. Case Reports ....................................................11 15 2.1.2. Epidemiologic Studies .............................................13 16 2.2. Nonlethal Toxicity .....................................................13 17 2.2.1. Case Reports ....................................................13 18 2.2.2. Occupational Exposures ...........................................14 19 2.2.3. Experimental Studies ..............................................15 20 2.3. Developmental/Reproductive Toxicity .....................................19 21 2.4. Genotoxicity ..........................................................19 22 2.5. Carcinogenicity .......................................................19 23 2.6. Summary.............................................................20 24 25 3. ANIMAL TOXICITY DATA................................................20 26 3.1. Acute Lethality ........................................................20 27 3.1.1. Rats ...........................................................20 28 3.1.2. Mice ...........................................................21 29 3.2. Nonlethal Toxicity .....................................................22 30 3.2.1. Nonhuman Primates ...............................................22 31 3.2.2. Dogs ...........................................................23 32 3.2.3. Rats ...........................................................24 33 3.2.4. Mice ...........................................................24 34 3.2.5. Rabbits .........................................................26 35 3.2.6. Guinea pigs .....................................................27 36 3.3. Developmental/Reproductive Toxicity .....................................27 37 3.4. Genotoxicity ..........................................................29 38 3.5. Carcinogenicity .......................................................29 39 3.6. Summary.............................................................29 40 41 4. SPECIAL CONSIDERATIONS..............................................30 42 4.1. Metabolism and Disposition ..............................................30 43 4.2. Mechanism of Toxicity .................................................31 44 4.3. Structure-Activity Relationships ..........................................32 45 4.4. Other Relevant Information ..............................................32 46 TABLE OF CONTENTS (Continued) 47 4 1,1,1-TRICHLOROETHANE INTERIM 1: 6\2000 1 4.4.1. Species Variability ................................................32 2 4.4.2. Susceptible Subpopulations .........................................33 3 4.4.3. Concentration-Response Relationship .................................33 4 5 5. DATA ANALYSIS FOR AEGL-1 ............................................34 6 5.1. Summary of Human Data Relevant to AEGL-1 ...............................34 7 5.2. Summary of Animal Data Relevant to AEGL-1 ..............................34 8 5.3. Derivation of AEGL-1 ..................................................35 9 10 6. DATA ANALYSIS FOR AEGL-2 ............................................35 11 6.1. Summary of Human Data Relevant to AEGL-2 ...............................35 12 6.2. Summary of Animal Data Relevant to AEGL-2 ..............................36 13 6.3. Derivation of AEGL-2 ..................................................36 14 15 7. DATA ANALYSIS FOR AEGL-3 ............................................37 16 7.1. Summary of Human Data Relevant to AEGL-3 ...............................37 17 7.2. Summary of Animal Data Relevant to AEGL-3 ..............................37 18 7.3. Derivation of AEGL-3 ..................................................37 19 20 8. SUMMARY OF PROPOSED AEGLS.........................................38 21 8.1. AEGL Values and Toxicity Endpoints ......................................38 22 8.2. Comparison with Other Standards and Guidelines ............................39 23 8.3. Data Quality and Research Needs .........................................40 24 25 9. REFERENCES ...........................................................41 26 27 APPENDIX A: Time-Scaling Calculations for 1,1,1-Trichloroethane ...................52 28 29 APPENDIX B: Derivation of AEGL Values.......................................55 30 31 APPENDIX C: Derivation Summary for 1,1,1-Trichloroethane AEGLs .................59 32 5 1,1,1-TRICHLOROETHANE INTERIM 1: 6\2000 1 LIST OF TABLES 2 3 Summary of Interim Values for 1,1,1-Trichloroethane .................................8 4 1. Chemical and Physical Data..................................................11 5 2. Effects of Exposure to 1,1,1-Trichloroethane in Humans ...........................17 6 3. Summary of Animal LC50 Toxicity Data With 1,1,1-Trichloroethane .................22 7 4. Summary of Animal Neurobehavioral Data with 1,1,1-Trichloroethane ...............25 8 5. AEGL-1 Values for 1,1,1-Trichloroethane .......................................35 9 6. AEGL-2 Values for 1,1,1-Trichloroethane .......................................37 10 7. AEGL-3 Values for 1,1,1-Trichloroethane .......................................38 11 8. Summary of AEGL Values...................................................38 12 9. Extant Standards and Guidelines for 1,1,1-Trichloroethane ..........................40 13 14 15 16 FIGURE 17 18 1. AEGL Values and Support Data for 1,1,1-Trichloroethane ..........................39 19 20 6 1,1,1-TRICHLOROETHANE INTERIM 1: 6\2000 1 EXECUTIVE SUMMARY 2 3 1,1,1-Trichloroethane is a colorless, nonflammable liquid used primarily as an industrial 4 metal degreasing agent. It is also used as a solvent for adhesives, inks, and coatings and as an 5 aerosol propellant (Kirk-Othmer, 1991; WHO, 1992). Solvent vapor is readily absorbed from 6 the respiratory tract and distributed throughout the body, accumulating in tissues with high lipid 7 content.
Load more

Recommended publications
  • Veterinary Emergency & Anaesthesia Pfizer
    AVA ECVA & AVEF Thank all their sponsors for this spring edition PARIS 2007 On VETERINARY EMERGENCY & ANAESTHESIA PFIZER MERIAL FORT DODGE BAYER BOEHRINGER MEDISUR COVETO OPTOMED HALLOWELL SCIL JANSSEN SOGEVAL KRUSSE TECHNIBELT MILA TEM The Organisatiors 7th AVEF European Meeting- 10th March 2007-ROISSY 2 AVA – ECVA Spring Meeting 2007 on Veterinary Emergency & Anesthesia 7 – 10 March 2007, Paris, France AVA PARIS 2007 — Wednesday March 7th RESIDENT DAY RUMINANT ANAESTHESIA Hyatt Regency Hotel, Roissy CDG, France K OTTO, D HOLOPHERNE, G TOUZOT 8.30 REGISTRATIONS 9.00-9.45 Specific anatomo-physiology to consider for ruminant peri-anaesthetic period K OTTO 10.00-10.30 COFFEE BREAK 10.30-11.15 Post-anaesthetic and pain management in ruminants K OTTO 11.30-12.15 Physical restraint and sedation of ruminants D HOLOPHERNE 12.30-1.30 LUNCH 1.30-2.15 Anaesthesia of Lamas & Alpagas G TOUZOT 2.30-3.15 Regional & local anaesthesia for ruminants D HOLOPHERNE 3.30-4.00 COFFEE BREAK 4.00-4.45 Pharmacology and protocols for ruminant anaesthesia G TOUZOT AVA-ECVA PARIS 2007, Veterinary Emergency & Anaesthesia, 7-10th March AVA-ECVA PARIS 2007, Veterinary Emergency & Anaesthesia, 7-10th March AVA – ECVA Spring Meeting 2007 on Veterinary Emergency & Anesthesia 7 – 10 March 2007, Paris, France Specific anatomo-physiology to consider for ruminants peri-anaesthetic period Klaus A. Otto Institut für Versuchstierkunde und Zentrales Tierlaboratorium, Medizinische Hochschule Hannover, D-30623 Hannover, Germany The suborder “ruminantia” includes members of the family “bovidae” such as cattle (bos taurus), sheep (ovis spp) and goats (capra spp). Members of the family “camelidae” (camelus spp, llama spp, vicugna spp) belong to the suborder “tylopodia” and therefore are not true ruminants.
    [Show full text]
  • PENTOBARBITAL SODIUM- Pentobarbital Sodium Injection Akorn, Inc
    PENTOBARBITAL SODIUM- pentobarbital sodium injection Akorn, Inc. ---------- Nembutal® Sodium Solution CII (pentobarbital sodium injection, USP) + novaplus TM Rx only Vials DO NOT USE IF MATERIAL HAS PRECIPITATED DESCRIPTION The barbiturates are nonselective central nervous system depressants which are primarily used as sedative hypnotics and also anticonvulsants in subhypnotic doses. The barbiturates and their sodium salts are subject to control under the Federal Controlled Substances Act (See “Drug Abuse and Dependence” section). The sodium salts of amobarbital, pentobarbital, phenobarbital, and secobarbital are available as sterile parenteral solutions. Barbiturates are substituted pyrimidine derivatives in which the basic structure common to these drugs is barbituric acid, a substance which has no central nervous system (CNS) activity. CNS activity is obtained by substituting alkyl, alkenyl, or aryl groups on the pyrimidine ring. NEMBUTAL Sodium Solution (pentobarbital sodium injection) is a sterile solution for intravenous or intramuscular injection. Each mL contains pentobarbital sodium 50 mg, in a vehicle of propylene glycol, 40%, alcohol, 10% and water for injection, to volume. The pH is adjusted to approximately 9.5 with hydrochloric acid and/or sodium hydroxide. NEMBUTAL Sodium is a short-acting barbiturate, chemically designated as sodium 5-ethyl-5-(1- methylbutyl) barbiturate. The structural formula for pentobarbital sodium is: The sodium salt occurs as a white, slightly bitter powder which is freely soluble in water and alcohol but practically insoluble in benzene and ether. CLINICAL PHARMACOLOGY Barbiturates are capable of producing all levels of CNS mood alteration from excitation to mild sedation, to hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia.
    [Show full text]
  • Management of Chronic Problems
    MANAGEMENT OF CHRONIC PROBLEMS INTERACTIONS BETWEEN ALCOHOL AND DRUGS A. Leary,* T. MacDonald† SUMMARY concerned. Alcohol may alter the effects of the drug; drug In western society alcohol consumption is common as is may change the effects of alcohol; or both may occur. the use of therapeutic drugs. It is not surprising therefore The interaction between alcohol and drug may be that concomitant use of these should occur frequently. The pharmacokinetic, with altered absorption, metabolism or consequences of this combination vary with the dose of elimination of the drug, alcohol or both.2 Alcohol may drug, the amount of alcohol taken, the mode of affect drug pharmacokinetics by altering gastric emptying administration and the pharmacological effects of the drug or liver metabolism. Drugs may affect alcohol kinetics by concerned. Interactions may be pharmacokinetic or altering gastric emptying or inhibiting gastric alcohol pharmacodynamic, and while coincidental use of alcohol dehydrogenase (ADH).3 This may lead to altered tissue may affect the metabolism or action of a drug, a drug may concentrations of one or both agents, with resultant toxicity. equally affect the metabolism or action of alcohol. Alcohol- The results of concomitant use may also be principally drug interactions may differ with acute and chronic alcohol pharmacodynamic, with combined alcohol and drug effects ingestion, particularly where toxicity is due to a metabolite occurring at the receptor level without important changes rather than the parent drug. There is both inter- and intra- in plasma concentration of either. Some interactions have individual variation in the response to concomitant drug both kinetic and dynamic components and, where this is and alcohol use.
    [Show full text]
  • Evaluating the Translational Potential of Progesterone Treatment Following
    Wong et al. BMC Neuroscience 2014, 15:131 http://www.biomedcentral.com/1471-2202/15/131 RESEARCH ARTICLE Open Access Evaluating the translational potential of progesterone treatment following transient cerebral ischaemia in male mice Raymond Wong1, Claire L Gibson2*, David A Kendall3 and Philip MW Bath1 Abstract Background: Progesterone is neuroprotective in numerous preclinical CNS injury models including cerebral ischaemia. The aim of this study was two-fold; firstly, we aimed to determine whether progesterone delivery via osmotic mini-pump would confer neuroprotective effects and whether such neuroprotection could be produced in co-morbid animals. Results: Animals underwent transient middle cerebral artery occlusion. At the onset of reperfusion, mice were injected intraperitoneally with progesterone (8 mg/kg in dimethylsulfoxide). Adult and aged C57 Bl/6 mice were dosed additionally with subcutaneous infusion (1.0 μl/h of a 50 mg/ml progesterone solution) via implanted osmotic minipumps. Mice were allowed to survive for up to 7 days post-ischaemia and assessed for general well-being (mass loss and survival), neurological score, foot fault and t-maze performance. Progesterone reduced neurological deficit [F(1,2) = 5.38, P = 0.027] and number of contralateral foot-faults [F(1,2) = 7.36, P = 0.0108] in adult, but not aged animals, following ischaemia. In hypertensive animals, progesterone treatment lowered neurological deficit [F(1,6) = 18.31, P = 0.0001], reduced contralateral/ipsilateral alternation ratio % [F(1,2) = 17.05, P = 0.0006] and time taken to complete trials [F(1,2) = 15.92, P = 0.0009] for t-maze. Conclusion: Post-ischemic progesterone administration via mini-pump delivery is effective in conferring functional improvement in a transient MCAO model in adult mice.
    [Show full text]
  • Deliberate Self-Poisoning with a Lethal Dose of Pentobarbital: Survival with Supportive Care
    Deliberate self-poisoning with a lethal dose of pentobarbital: Survival with supportive care. (1) (1,2) Santosh Gone , Andis Graudins (1) Clinical Toxicology Service, Program of Emergency Medicine, Monash Health (2) Monash Emergency Research Collaboration, Clinical Sciences at Monash Health, Monash University Abstract 84 INTRODUCTION CASE REPORT (continued) DISCUSSION Pentobarbital (Nembutal) is short acting In the ED: Pentobarbital has been a banned substance for barbiturate sedative-hypnotic, currently widely GCS: 3/15, fixed dilated pupils, apnoeic and human use in Australia since 1998. However, it can used in veterinary practice for anesthesia and ventilated. be procured overseas or bought on the internet. euthanasia. Pulse: 116 bpm sinus tachycardia BP: 115/60 on epinephrine infusion. Pentobarbital is recommended as an effective It is also commonly recommended as a VBG: pH 7.03 pCO2 77 mmHg Bicarb 19 mmol/L agent for use in euthanasia due to its apparently euthanasia drug for assisted suicide and it is Lactate 8.8 mmol/L peaceful transition to death. unlikely that any resuscitative measures will be Activated charcoal (50g) given via an NG tube. attempted in such cases. Course in the Intensive Care Department: In a case series of 150 assisted suicides in Day-1 post-OD: Sweden, a 100% success rate was seen with Intentional overdose results in depression of - Absent brain stem reflexes and fixed dilated pupils for ingestion of 9 grams. Cardiovascular collapse was brain stem function and rapid onset respiratory five days. seen within 15 minutes in 30% of patients. It is rare depression and apnoea. Hypotension also - Diabetes insipidus developed with urine output of to see survival after intentional ingestion for develops, followed by cardiovascular collapse 300ml/hour.
    [Show full text]
  • Euthanasia of Experimental Animals
    EUTHANASIA OF EXPERIMENTAL ANIMALS • *• • • • • • • *•* EUROPEAN 1COMMISSIO N This document has been prepared for use within the Commission. It does not necessarily represent the Commission's official position. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int) Cataloguing data can be found at the end of this publication Luxembourg: Office for Official Publications of the European Communities, 1997 ISBN 92-827-9694-9 © European Communities, 1997 Reproduction is authorized, except for commercial purposes, provided the source is acknowledged Printed in Belgium European Commission EUTHANASIA OF EXPERIMENTAL ANIMALS Document EUTHANASIA OF EXPERIMENTAL ANIMALS Report prepared for the European Commission by Mrs Bryony Close Dr Keith Banister Dr Vera Baumans Dr Eva-Maria Bernoth Dr Niall Bromage Dr John Bunyan Professor Dr Wolff Erhardt Professor Paul Flecknell Dr Neville Gregory Professor Dr Hansjoachim Hackbarth Professor David Morton Mr Clifford Warwick EUTHANASIA OF EXPERIMENTAL ANIMALS CONTENTS Page Preface 1 Acknowledgements 2 1. Introduction 3 1.1 Objectives of euthanasia 3 1.2 Definition of terms 3 1.3 Signs of pain and distress 4 1.4 Recognition and confirmation of death 5 1.5 Personnel and training 5 1.6 Handling and restraint 6 1.7 Equipment 6 1.8 Carcass and waste disposal 6 2. General comments on methods of euthanasia 7 2.1 Acceptable methods of euthanasia 7 2.2 Methods acceptable for unconscious animals 15 2.3 Methods that are not acceptable for euthanasia 16 3. Methods of euthanasia for each species group 21 3.1 Fish 21 3.2 Amphibians 27 3.3 Reptiles 31 3.4 Birds 35 3.5 Rodents 41 3.6 Rabbits 47 3.7 Carnivores - dogs, cats, ferrets 53 3.8 Large mammals - pigs, sheep, goats, cattle, horses 57 3.9 Non-human primates 61 3.10 Other animals not commonly used for experiments 62 4.
    [Show full text]
  • Pentobarbital Sodium
    PENTobarbital Sodium Brand names Nembutal Sodium Medication error Look-alike, sound-alike drug names. Tall man letters (not FDA approved) are recommended potential to decrease confusion between PENTobarbital and PHENobarbital.(1,2) ISMP recommends the following tall man letters (not FDA approved): PENTobarbital.(30) Contraindications Contraindications: In patients with known hypersensitivity to barbiturates or any com- and warnings ponent of the formulation.(2) If an allergic or hypersensitivity reaction or a life-threatening adverse event occurs, rapid substitution of an alternative agent may be necessary. If pentobarbital is discontinued due to development of a rash, an anticonvulsant that is structurally dissimilar should be used (i.e., nonaromatic). (See Rare Adverse Effects in the Comments section.) Also contraindicated in patients with a history of manifest or latent porphyria.(2) Warnings: Rapid administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with hypotension.(2) Should be withdrawn gradually if large doses have been used for prolonged periods.(2) Paradoxical excitement may occur or important symptoms could be masked when given to patients with acute or chronic pain.(2) May be habit forming. Infusion-related Respiratory depression and arrest requiring mechanical ventilation may occur. Monitor cautions oxygen saturation. If hypotension occurs, the infusion rate should be decreased and/or the patient should be treated with IV fluids and/or vasopressors. Pentobarbital is an alkaline solution (pH = 9–10.5); therefore, extravasation may cause tissue necrosis.(2) (See Appendix E for management.) Gangrene may occur following inadvertent intra-arterial injection.(2) Dosage Medically induced coma (for persistently elevated intracranial pressure (ICP) or refractory status epilepticus): Patient should be intubated and mechanically ventilated.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Calcium Current Block by (-)-Pentobarbital, Phenobarbital
    The Journal of Neuroscience, August 1993, 13(E): 321 l-3221 Calcium Current Block by (-)-Pentobarbital, Phenobarbital, and CHEB but not (+)-Pentobarbital in Acutely Isolated Hippocampal CA1 Neurons: Comparison with Effects on GABA-activated Cl- Current Jarlath M. H. ffrench-Mullen,’ Jeffery L. Barker,* and Michael A. Rogawski3 ‘Department of Pharmacology, Zeneca Pharmaceuticals Group, Zeneca Inc., Wilmington, Delaware 19897 and *Laboratory of Neurophysiology, and 3Neuronal Excitability Section, Epilepsy Research Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892 Block of a voltage-activated Ca*+ channel current by pheno- Ca*+ current, whereas the sedative effects that occur at high- barbital (PHB), 5-(2-cyclohexylideneethyl)-5-ethyl barbituric er concentrations could reflect stronger Ca2+ current block- acid (CHEB), and the optical R(-)- and S(+)-enantiomers of ade. The powerful sedative-hypnotic action of (-)-PB may pentobarbital (PB) was examined in freshly dissociated adult reflect greater maximal enhancement of GABA responses guinea pig hippocampal CA1 neurons; the effects of the in conjunction with strong inhibition of Ca2+ current. The barbiturates on GABA-activated Cl- current were also char- convulsant action of CHEB is unlikely to be related to its acterized in the same preparation. (-)-PB, PHB, and CHEB effects on the Ca*+ current. produced a reversible, concentration-dependent block of the [Key words: calcium channel, GABA receptor, (-)-pen- peak Ca*+ channel current (3 mM Ba2+ as the charge carrier) tobarbital, (+)-pentobarbital, phenobarbital, CHEB [S-(2-cy- evoked by depolarization from -80 to - 10 mV (I&,, values, clohexylideneethyl)-S-ethyl barbituric acid], CA 1 hippocam- 3.5, 72, and 118 PM, respectively).
    [Show full text]
  • FORANE (Isoflurane, USP)
    Forane ® (isoflurane, USP) Proposed Package Insert FORANE (isoflurane, USP) Liquid For Inhalation Rx only DESCRIPTION FORANE (isoflurane, USP), a nonflammable liquid administered by vaporizing, is a general inhalation anesthetic drug. It is 1-chloro-2, 2,2-trifluoroethyl difluoromethyl ether, and its structural formula is: Some physical constants are: Molecular weight 184.5 Boiling point at 760 mm Hg 48.5°C (uncorr.) 20 1.2990-1.3005 Refractive index n D Specific gravity 25°/25°C 1.496 Vapor pressure in mm Hg** 20°C 238 25°C 295 30°C 367 35°C 450 **Equation for vapor pressure calculation: log10Pvap = A + B where A = 8.056 T B = -1664.58 T = °C + 273.16 (Kelvin) Partition coefficients at 37°C: Water/gas 0.61 Blood/gas 1.43 Oil/gas 90.8 1 Forane ® (isoflurane, USP) Proposed Package Insert Partition coefficients at 25°C – rubber and plastic Conductive rubber/gas 62.0 Butyl rubber/gas 75.0 Polyvinyl chloride/gas 110.0 Polyethylene/gas ~2.0 Polyurethane/gas ~1.4 Polyolefin/gas ~1.1 Butyl acetate/gas ~2.5 Purity by gas >99.9% chromatography Lower limit of None flammability in oxygen or nitrous oxide at 9 joules/sec. and 23°C Lower limit of Greater than useful concentration in flammability in oxygen anesthesia. or nitrous oxide at 900 joules/sec. and 23°C Isoflurane is a clear, colorless, stable liquid containing no additives or chemical stabilizers. Isoflurane has a mildly pungent, musty, ethereal odor. Samples stored in indirect sunlight in clear, colorless glass for five years, as well as samples directly exposed for 30 hours to a 2 amp, 115 volt, 60 cycle long wave U.V.
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • Appendix D: Important Facts About Alcohol and Drugs
    APPENDICES APPENDIX D. IMPORTANT FACTS ABOUT ALCOHOL AND DRUGS Appendix D outlines important facts about the following substances: $ Alcohol $ Cocaine $ GHB (gamma-hydroxybutyric acid) $ Heroin $ Inhalants $ Ketamine $ LSD (lysergic acid diethylamide) $ Marijuana (Cannabis) $ MDMA (Ecstasy) $ Mescaline (Peyote) $ Methamphetamine $ Over-the-counter Cough/Cold Medicines (Dextromethorphan or DXM) $ PCP (Phencyclidine) $ Prescription Opioids $ Prescription Sedatives (Tranquilizers, Depressants) $ Prescription Stimulants $ Psilocybin $ Rohypnol® (Flunitrazepam) $ Salvia $ Steroids (Anabolic) $ Synthetic Cannabinoids (“K2”/”Spice”) $ Synthetic Cathinones (“Bath Salts”) PAGE | 53 Sources cited in this Appendix are: $ Drug Enforcement Administration’s Drug Facts Sheets1 $ Inhalant Addiction Treatment’s Dangers of Mixing Inhalants with Alcohol and Other Drugs2 $ National Institute on Alcohol Abuse and Alcoholism’s (NIAAA’s) Alcohol’s Effects on the Body3 $ National Institute on Drug Abuse’s (NIDA’s) Commonly Abused Drugs4 $ NIDA’s Treatment for Alcohol Problems: Finding and Getting Help5 $ National Institutes of Health (NIH) National Library of Medicine’s Alcohol Withdrawal6 $ Rohypnol® Abuse Treatment FAQs7 $ Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) Keeping Youth Drug Free8 $ SAMHSA’s Center for Behavioral Health Statistics and Quality’s (CBHSQ’s) Results from the 2015 National Survey on Drug Use and Health: Detailed Tables9 The substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15.10 Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the United States, their relative abuse potential, and likelihood of causing dependence when abused.
    [Show full text]